Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine

Archives of Virology, Supplement

Volumn 1996, Issue 12, 1996, Pages 163-175

  Kapikian, A Z ^a   Hoshino, Y ^a   Chanock, R M ^a   Perez Schael, I ^b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT VACCINE; VIRUS VACCINE;

ANIMAL; CLINICAL TRIAL; DIARRHEA; HUMAN; IMMUNOLOGY; MACACA; REVIEW; VACCINATION; VIROLOGY; VIRUS INFECTION;

ANIMALS; CLINICAL TRIALS; DIARRHEA; HUMANS; MACACA MULATTA; ROTAVIRUS INFECTIONS; VACCINATION; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 0030339677     PISSN: 09391983     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-3-7091-6553-9_18     Document Type: Article

References (30)

1. Bernstein DI, Glass RI, Rogers G, Davidson BL, Sack DA, for the U.S. Rotavirus Vaccine Efficacy Group (1995) Evaluation of rhesus rotavirus monovalent and tetravalent reassortant vaccines in US children. JAMA 273: 1191-1196
2. Bishop RF, Barnes GL, Cipriani E, Lund JS (1983) Clinical immunity after neonatal rotavirus infection. A prospective longitudinal study in young children. N Engl J Med 309: 72-76
3. Flores J, Perez-Schael I, Blanco M, White L, Garcia D, Vilar M, Cunto W, Gonzalez R, Urbina C, Boher J, Mendez M, Kapikian AZ (1990) Comparison of reactogenicity and antigenicity of M37 rotavirus vaccine and rhesus-rotavirus-based quadrivalent vaccine. Lancet 336: 330-334
4. Flores J, Perez-Schael I, Blanco M, Rojas AM, Alfonzo E, Crespo I, Cunto W, Pittman A, Kapikian AZ (1993) Reactogenicity and immunogenicity of a high-titered rhesus rotavirus-based quadrivalent rotavirus vaccine. J Clin Microbiol 31: 2439-2445
5. Ho M-S, Glass RI, Pinsky PF, Young-Okoh N, Sappenfield WM, Buehler JW, Gunter N, Anderson LJ (1988) Diarrheal deaths in American children. Are they preventable? JAMA 260: 3281-3285
6. Hoshino Y, Kapikian AZ (1994) Rotavirus vaccine development for the prevention of severe diarrhea in infants and young children. Trends Microbiol 2: 242-249
7. Hoshino Y, Kapikian AZ, Chanock RM (1994) Selection of cold-adapted mutants of human rotaviruses that exhibit various degrees of growth restriction in vitro. J Virol 68: 7598-7602
8. Hoshino Y, Saif L, Kang S-Y, Sereno MM, Chen W-K, Kapikian AZ (1995) Identification of group A rotavirus genes associated with virulence of a porcine rotavirus and host range restriction of a human rotavirus in the gnotobiotic piglet model. Virology 209: 274-280
9. Institute of Medicine (1986) Prospects for immunizing against rotavirus. In: New Vaccine Development. Establishing Priorities. Diseases of Importance in the United States, vol 1. National Academy Press, Washington, DC, pp 410-423
10. Institute of Medicine (1986) The prospects for immunizing against rotavirus. In: New Vaccine Development. Establishing Priorities. Diseases of Importance in Developing Countries, vol 2. National Academy Press, Washington, DC, pp 308-316
11. Kapikian AZ (1994) Jennerian and modified Jennerian approach to vaccination against rotavirus diarrhea in infants and young children: an introduction. In: Kapikian AZ (ed) Viral Infections of the Gastrointestinal Tract. Marcel Dekker, New York, pp 409-417
12. Kapikian AZ (1994) Rhesus rotavirus-based human rotavirus vaccines and observations on selected non-Jennerian approaches to rotavirus vaccination. In: Kapikian AZ (ed) Viral Infections of the Gastrointestinal Tract. Marcel Dekker, New York, pp 443-470
13. Kapikian AZ, Chanock RM (1996) Rotaviruses. In: Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (eds) Virology. Lippincott-Raven Publishers, Philadelphia, pp 1657-1708
14. Kapikian AZ, Cline WL, Kim HW, Kalica AR, Wyatt RG, VanKirk DH, Chanock RM, James HD Jr, Vaughn AL (1976) Antigenic relationships among five reovirus-like (RVL) agents by complement-fixation (CF) and development of new substitute CF antigens for the human RVL agent of infantile gastroenteritis. Proc Soc Exp Biol Med 152: 535-539
15. Kapikian AZ, Hoshino Y, Flores J, Midthun K, Glass RI, Nakagomi O, Nakagomi T, Chanock RM, Potash L, Levine MM, Dolin R, Wright PF, Belshe RE, Anderson EL, Vesikari T, Gothefors L, Wadell G, Perez-Schael I (1986) In: Holmgren J, Lindberg A, Mollby R (eds) Development of Vaccines and Drugs Against Diarrhea. 11th Nobel Conference, Stockholm 1985. Student litteratur, Lund, Sweden, pp 192-214
16. Kapikian AZ, Vesikari T, Ruuska T, Madore HP, Christy C, Dolin R, Flores J, Green KY, Davidson BL, Gorziglia M, Hoshino Y, Chanock RM, Midthun K, Perez-Schael I (1992) An update on the "Jennerian" and modified "Jennerian" approach to vaccination of infants and young children against rotavirus diarrhea. Adv Exp Med Biol 327: 59-69
17. Kapikian AZ, Wyatt RG, Levine MM, Black RE, Greenberg HB, Flores J, Kalica AR, Hoshino Y, Chanock RM (1983) Studies in volunteers with human rotaviruses. Dev Biol Stand 53: 209-218
18. Madore HP, Christy C, Pichichero M, Long C, Pincus P, Vosefsky P, Kapikian AZ, Dolin R, Elmwood, Panorama, and Westfall Pediatric Groups (1992) Field trial of rhesus rotavirus or human-rhesus reassortant vaccine of VP7 serotype 3 or 1 specificity in infants. J Infect Dis 166: 235-243
19. Mattion NM, Cohen J, Estes MK (1994) The rotavirus proteins. In: Kapikian AZ (ed) Viral Infections of the Gastrointestinal Tract. Marcel Dekker, New York, pp 169-249
20. Midthun K, Greenberg HB, Hoshino Y, Kapikian AZ, Wyatt RG, Chanock RM (1985) Reassortant rotaviruses as potential live rotavirus vaccine candidates. J Virol 53: 949-954
21. Midthun K, Hoshino Y, Kapikian AZ, Chanock RM (1986) Single gene substitution rotavirus reassortants containing the major neutralization protein (VP7) of human rotavirus serotype 4. J Clin Microbiol 24: 822-826
22. Perez-Schael I, Garcia D, Gonzalez M, Gonzalez R, Daoud N, Perez M, Cunto W, Kapikian AZ, Flores J (1990) Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine. J Med Virol 30: 219-229
23. Prasad BV, Burns JW, Marietta E, Estes MK, Chiu W (1990) Localization of VP4 neutralization sites in rotavirus by three-dimensional cryo-electron microscopy. Nature 343: 476-479
24. Rennels MB, Glass RI, Dennehy PH, Bernstein DI, Pichichero ME, Zito ET, Mack ME, Davidson BL, Kapikian AZ, for the United States Rotavirus Efficacy Group (1996) Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines-report of the national multicenter trial. Pediatrics 97: 7-13
25. Vesikari T, Ruuska T, Green KY, Flores J, Kapikian AZ (1992) Protective efficacy against serotype 1 rotavirus diarrhea by live oral rhesus-human reassortant rotavirus vaccines with human rotavirus VP7 serotype 1 or 2 specificity. Pediatr Inf Dis J 11: 535-542
26. Vesikari T, Ruuska T, Kouvu HP, Green KY, Flores J, Kapikian AZ (1991) Evaluation of the M37 human rotavirus vaccine in 2- to 6-month old infants. Pediatr Inf Dis J 10: 912-917
27. Wallace RE, Vasington PJ, Petricciani JC, Hopps HE, Lorenz DE, Kadanka Z (1973) Development of a diploid cell line from fetal rhesus monkey lung for virus vaccine production. In Vitro 8: 323-332
28. World Health Organization Scientific Working Group (1980) Rotavirus and other viral diarrheas. Bull WHO 58: 183-198
29. Wyatt RG, Kapikian AZ, Hoshino Y, Flores J, Midthun K, Greenberg HB, Glass RI, Askaa J, Levine MM, Black RE, Clements ML, Potash L, London WT (1985) In Control and Eradication of Infectious Diseases. An International Symposium PAHO copublication series no. 1, Washington, DC, Pan American Health Organization, pp 17-28
30. Wyatt RG, Mebus CA, Yolken RH, Kalica AR, James HD Jr, Kapikian AZ, Chanock RM (1979) Rotaviral immunity in gnotobiotic calves: Heterologous resistance to human virus induced by bovine virus. Science 203: 548-550